Humana Inc. (HUM) Stock Price & Analysis
Humana Inc. (HUM) closed at USD 420.97 on Thursday, October 22, 2026, down 1.05% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 425.42; the Oct 22, 2026 session ranged USD 417.5–428.31 on volume of 1,811,696 shares. Market capitalization is $50.55B, with a 52-week range of USD 163.11–456.5 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:28 UTC.
Also available as compact Markdown for AI agents: nexqual.com/HUM.md
Key facts (HUM)
- Last four reported quarters (through Jun 30, 2026): revenue $146B, net income $1.28B (0.9% margin), free cash flow $1.95B (SEC filings).
- Valuation: P/E 39.5x (avg 24.8x at the last 3 fiscal year-ends), EV/EBITDA 12.2x, net cash $9.62B.
- 2 of 80 tracked superinvestors hold HUM (13F, Q2 2026): 0 new, 0 added, 2 reduced, 0 unchanged.
- Analysts: Buy (mean 2.31 on a 1–5 scale) (26 analysts), mean target USD 465.13 (range 280–596).
- Total return with dividends: 1Y +46.1% vs S&P 500 +14.9%; 5Y -4.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-06, EPS estimate USD -1, revenue estimate $40.9B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (HUM)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $83.1B | $92.9B | $106B | $118B | $130B | $146B |
| Operating income | $3.15B | $3.80B | $4.01B | $2.56B | $2.70B | $2.71B |
| Net income | $2.93B | $2.81B | $2.49B | $1.21B | $1.19B | $1.28B |
| EPS (diluted) | $22.67 | $22.08 | $20.00 | $9.98 | $9.84 | — |
| Free cash flow | $920M | $3.45B | $2.98B | $2.39B | $375M | $1.95B |
| Operating margin | 3.8% | 4.1% | 3.8% | 2.2% | 2.1% | 1.9% |
| Net margin | 3.5% | 3.0% | 2.3% | 1.0% | 0.9% | 0.9% |
| Revenue growth | +7.7% | +11.8% | +14.5% | +10.7% | +10.1% | — |
| Cash + short-term investments | $16.6B | $18.9B | $21.3B | $20.4B | $19.9B | — |
| Total debt | $12.5B | $11.1B | $11.7B | $11.7B | $12.4B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (HUM)
P/E 39.5x · P/S 0.3x · EV/EBITDA 12.2x · EV/Sales 0.3x · P/FCF 25.9x · P/B 2.6x · FCF yield 3.86% · Earnings yield 2.53% · Dividend yield (paid, TTM) 0.85% · Buyback yield (TTM) 0.30% · Net cash $9.62B · EV $40.9B
P/E at fiscal year-ends: Dec 2025 26.0x, Dec 2024 25.4x, Dec 2023 22.9x.
Superinvestors (SEC 13F-HR, Q2 2026) (HUM)
2 of 80 tracked investors hold HUM. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Richard Pzena | Pzena Investment Management | 5.13% | $1.75B | Reduced -19.5% |
| Dodge & Cox Funds | Dodge & Cox | 2.28% | $4.35B | Reduced -3.9% |
Analysts (HUM)
Consensus Buy (mean 2.31 on a 1–5 scale), 26 analysts; mean target USD 465.13 (low 280, high 596).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Mizuho | Target raised | Outperform | $468 → $495 |
| 2026-10-12 | UBS | Target raised | Neutral | $405 → $495 |
| 2026-10-12 | Truist Securities | Target raised | Hold | $415 → $475 |
| 2026-10-12 | Oppenheimer | Target raised | Outperform | $475 → $525 |
| 2026-10-12 | Raymond James | Upgrade | Market Perform → Outperform | $520 |
| 2026-10-09 | Barclays | Target raised | Overweight | $515 → $582 |
| 2026-10-09 | Oppenheimer | Target raised | Outperform | $405 → $475 |
| 2026-10-09 | Baird | Upgrade | Neutral → Outperform | $390 → $596 |
| 2026-10-07 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | $300 → $460 |
| 2026-09-25 | Barclays | Upgrade | Equal-Weight → Overweight | $407 → $515 |
| 2026-08-10 | JP Morgan | Target raised | Neutral | $316 → $393 |
| 2026-08-05 | Morgan Stanley | Upgrade | Underweight → Equal-Weight | $249 → $370 |
Total return (dividends reinvested) (HUM)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +46.1% | -4.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +46.3% | -0.9% |
| Volatility (annualized) | 47.7% | 40.0% |
| Max drawdown | -44.3% (Oct 2025→Mar 2026) | -69.2% (Oct 2022→Mar 2026) |
Companies that name HUM in their SEC reports
| Relationship to HUM | Company | Filing | Sentence |
|---|---|---|---|
| partner | SelectQuote, Inc. (SLQT) | 10-K Aug 25, 2026 | “We represent approximately 20 leading, nationally-recognized insurance carrier partners, including carriers owned by UnitedHealthcare ("UHC"), Humana, Wellcare, and Aetna.” |
HUM analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-1.00 | $-0.14 | +607.6% | $40.89B | 23 |
| Next quarter (ends Dec 2026) | $-7.86 | $-8.17 | -3.7% | $41.26B | 23 |
| Current fiscal year (ends Dec 2026) | $9.16 | $8.96 | +2.3% | $162.74B | 26 |
| Next fiscal year (ends Dec 2027) | $17.09 | $16.03 | +6.6% | $168.69B | 26 |
Key Statistics (as of October 23, 2026 at 09:28 UTC)
| Price | USD 420.97 |
|---|---|
| Change | ▼ 1.05% (down) |
| Previous Close | USD 425.42 |
| Open | USD 423.16 |
| Day Range | USD 417.5 – 428.31 |
| 52-Week Range | USD 163.11 – 456.5 |
| Volume | 1,811,696 shares |
| Market Cap | $50.55B |
| Exchange | NYQ |
Technical Analysis (HUM)
Nexqual's technical model rates HUM "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:28 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.7 (neutral) |
| vs SMA50 | Above (USD 397.05) |
| MACD | 9.13 (positive) |
Analyst Ratings (HUM)
Wall Street analysts rate HUM "Buy" based on 26 analysts, with a mean price target of USD 465.13 (range USD 280–596), per Nexqual as of October 23, 2026 at 09:28 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 26 |
| Mean Target | USD 465.13 |
| High Target | USD 596 |
| Low Target | USD 280 |
| Buy / Hold / Sell | 16 / 9 / 1 |
Earnings (HUM)
| Next Earnings Date | 2026-11-06 |
|---|---|
| EPS Estimate | USD -1 |
| Revenue Estimate | $40.89B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 7.61 vs est 7 ▲ beat |
| 2026-03-31 | USD 10.31 vs est 10.2 ▲ beat |
| 2025-12-31 | USD -3.96 vs est -3.99 ▲ beat |
| 2025-09-30 | USD 3.24 vs est 2.83 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Financials & Fundamentals (HUM)
| Total Revenue | $145.68B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +26.20% |
| Gross Margin | +13.65% |
| Operating Margin | +3.46% |
| Profit Margin | +0.88% |
| ROE | +6.89% |
| Debt / Equity | 0.76 |
| Current Ratio | 1.74 |
| Total Cash | $23.87B |
| Total Debt | $14.74B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $1.95B (1.3% of revenue) |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Financial Health Score (HUM)
Nexqual rates Humana Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:28 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 14%, operating 3% (last 12 months) |
| Balance Sheet | Mixed — $23.9B cash and investments vs $14.2B debt (Jun 2026, SEC), net cash |
| Cash Flow | Mixed — FCF $1.95B (last 4 quarters to Jun 2026, SEC), slim 1.3% margin |
| Efficiency | Mixed — ROE 7%, ROA 3.9% |
Ownership (HUM)
| Insider Ownership | +0.21% |
|---|---|
| Institutional Ownership | +102.06% |
| Shares Outstanding | 120.08M |
| Float | 119.83M |
| Short % of Float | +2.64% |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Leadership (HUM)
Humana Inc. is led by James A. Rechtin, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:28 UTC.
| President, CEO & Director | James A. Rechtin |
|---|---|
| Chief Financial Officer | Celeste Marie Mellet |
| President of CenterWell | Sanjay K. Shetty |
| Senior VP & CTO | Bobby Mukundan |
| Vice President of Investor Relations | Lisa M. Stoner |
Major Backers & Investors (HUM)
Notable institutional backers of Humana Inc. include Dodge & Cox Inc., Pzena Investment Management LLC, Eagle Capital Management LLC, according to Nexqual as of October 23, 2026 at 09:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 9.11% |
| Pzena Investment Management LLC | 3.67% |
| Eagle Capital Management LLC | 3.2% |
| Sessa Capital IM, L.P. | 3.1% |
| Massachusetts Financial Services Co. | 2.98% |
| AMERICAN FUNDS FUNDAMENTAL INVESTORS | 1.41% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.38% |
| BlackRock | 8.68% |
| State Street | 4.54% |
| Geode Capital | 2.81% |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CNC | Centene Corporation | USD 71.24 | ▲ 1.42% |
| CI | The Cigna Group | USD 315.88 | ▲ 3.78% |
| ELV | Elevance Health, Inc. | USD 445.28 | ▲ 2.57% |
| CVS | CVS Health Corporation | USD 94.48 | ▲ 1.1% |
| MOH | Molina Healthcare Inc | USD 216.64 | ▲ 0.81% |
| OSCR | Oscar Health, Inc. | USD 33.32 | ▼ 0.39% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:28 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt